CNTFR Gene

📖 Wiki Page

gene1645 wordssynced 2026-04-02

CNTFR Gene

Introduction

...

CNTFR Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CNTFR Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CNTFR</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Ciliary Neurotrophic Factor Receptor Alpha</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>9p13.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>1271</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000122756</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P26992</td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein coding</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>118400</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Recombinant CNTF</td>
<td>Clinical trials</td>
</tr>
<tr>
<td class="label">CNTFR-Fc fusion</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">AAV-CNTR gene therapy</td>
<td>Development</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>Type</td>
</tr>
<tr>
<td class="label">R228C</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">P406L</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">Splice variants</td>
<td>Alternative splicing</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Role</td>
</tr>
<tr>
<td class="label">CNTFRα</td>
<td>Ligand-binding subunit</td>
</tr>
<tr>
<td class="label">GP130</td>
<td>Signal-transducing subunit[@liu2023]</td>
</tr>
<tr>
<td class="label">LIFRβ</td>
<td>Co-receptor subunit</td>
</tr>
<tr>
<td class="label">Species</td>
<td>CNTFR</td>
</tr>
<tr>
<td class="label">Human</td>
<td>CNTFRα</td>
</tr>
<tr>
<td class="label">Mouse</td>
<td>Cntfrα</td>
</tr>
<tr>
<td class="label">Rat</td>
<td>Cntfrα</td>
</tr>
<tr>
<td class="label">Zebrafish</td>
<td>cntfr</td>
</tr>
<tr>
<td class="label">Drosophila</td>
<td>DCNTFR</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">ALS (1990s)</td>
<td>Phase I/II</td>
</tr>
<tr>
<td class="label">Parkinson's</td>
<td>Phase I/II</td>
</tr>
<tr>
<td class="label">Huntington's</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

The CNTFR gene (Ciliary Neurotrophic Factor Receptor Alpha) encodes the alpha subunit of the CNTFR receptor complex, a critical component for CNTF-mediated signaling in the nervous system. CNTFRα is the high-affinity binding component that initiates CNTF signaling, which is essential for neuronal survival, differentiation, and function. The receptor is expressed throughout the central and peripheral nervous system and has significant implications for neurodegenerative disease research and therapy[@benhamou2023].

Gene Overview

Gene and Protein Structure

Chromosomal Organization

The CNTFR gene is located on chromosome 9p13.2 and spans approximately 22 kb of genomic DNA. The gene consists of 8 exons encoding a protein of 400 amino acids with a molecular weight of approximately 45 kDa[@chen2022].

Protein Domain Architecture

The CNTFRα protein is a member of the cytokine receptor family:

Extracellular cytokine-binding domain (CBD): Contains approximately 300 amino acids with fibronectin type III repeats
N-terminal signal peptide: Targets protein for secretion
GPI anchor sequence: C-terminal signal for membrane attachment
Multiple N-linked glycosylation sites: Important for protein folding and stability

Splice Variants

Multiple CNTFR splice variants have been identified[@park2024]:

Full-length membrane-bound: Primary functional variant
Soluble CNTFR: Lacks GPI anchor, circulates as a decoy receptor
Alternative splicing: Produces variants with altered ligand binding

Protein Product and Receptor Complex

The CNTFRα protein is a glycosylphosphatidylinositol (GPI)-anchored protein that serves as the ligand-binding component of the CNTF receptor complex. It lacks a transmembrane domain and is attached to the cell membrane via a GPI anchor. Together with GP130 and LIFRβ, it forms the functional signaling receptor for CNTF and related cytokines[@chen2022].

Receptor Complex Formation

Mermaid diagram (expand to render)

Function

CNTFRα mediates essential biological functions[@engeland2023]:

Cytokine Binding: High-affinity binding of CNTF

Receptor Complex Formation: Recruits GP130 and LIFRβ

Signal Transduction: Initiates JAK-STAT pathway

Neuronal Survival: Mediates neurotrophic effects

Development: Critical for nervous system development

Astrocyte Function: Regulates astrocyte reactivity[@singh2023]

Signaling Mechanisms

JAK/STAT Pathway: Primary CNTF signaling[@nakamura2023]
STAT3 Activation: Main transcription factor
MAPK Pathway: Secondary signaling
PI3K/Akt Pathway: Pro-survival signaling

Expression Pattern

CNTFR is widely expressed in the nervous system[@benhamou2023]:

Brain: Cortex, hippocampus, cerebellum, basal ganglia
Spinal cord: Motor neurons, interneurons
Peripheral nervous system: Sensory neurons, Schwann cells
Astrocytes: Modulates neuroinflammation
Neural stem cells: Regulates differentiation[@kim2023]

Role in Neurodegeneration

Alzheimer's Disease

CNTFR has significant implications in AD[@huang2022][@wang2023]:

CNTF/CNTFR signaling is altered in AD brains: Reduced expression observed in hippocampal and cortical regions
Protection against amyloid-beta toxicity: CNTF activation prevents neuronal apoptosis through activation of anti-apoptotic proteins
The pathway may be impaired in AD: Contributes to disease progression through loss of neurotrophic support
Therapeutic potential: CNTFR agonists may restore neuroprotective signaling in AD patients
Synaptic function: CNTFR signaling supports synaptic plasticity and memory formation
Neuroinflammation modulation: The pathway regulates astrocyte-mediated inflammatory responses

Parkinson's Disease

The receptor is highly relevant to PD[@yang2022][@gao2023]:

Expressed in dopaminergic neurons: High levels in substantia nigra pars compacta
CNTF can protect substantia nigra neurons: Prevents dopaminergic cell death in toxin-based models
Gene therapy approaches: AAV-mediated CNTFR expression in development for sustained delivery
Enhances dopamine neuron survival: Through JAK-STAT signaling and anti-apoptotic mechanisms
Mitochondrial protection: CNTFR activation preserves mitochondrial function in dopaminergic neurons
Motor behavior improvement: CNTF treatment improves motor function in PD animal models

Motor Neuron Disease (ALS)

CNTFR is essential for motor neuron function[@liu2023][@tateishi2022]:

Motor neurons express high CNTFR levels: Critical for survival
CNTF delivery tested in ALS: Clinical trials conducted
AAV-mediated CNTFR overexpression: Shows promise in mouse models
Gene therapy approaches: Target the receptor for treatment

Neuroinflammatory Conditions

CNTFR modulates neuroinflammation through[@singh2023]:

Astrocyte reactivity: Regulates inflammatory responses
Microglial activation: Modulates CNS immune status
Cytokine production: Controls pro-inflammatory mediator release

Therapeutic Targeting

Current Approaches

Agonists and Modulators

CNTFR-Fc: Soluble receptor fusion proteins with enhanced stability
Modified CNTF variants: Engineered for reduced side effects
Small molecule agonists: In development

Gene Therapy Progress

Recent advances in gene therapy have improved CNTF/CNTFR delivery[@muller2022][@gao2023]:

AAV vectors: Efficient CNS transduction
Targeted delivery: Intrathecal or stereotactic injection
Controlled expression: Regulated promoters
Primate studies: Safety and efficacy demonstrated[@xu2024]

Clinical Considerations

Side effects limit systemic CNTF use
Intrathecal delivery being explored
Biomarkers for patient selection needed
Combination approaches considered

Genetic Associations

Disease-Associated Variants

CNTFR polymorphisms have been associated with multiple conditions[@davis2024]:

ALS risk: Specific variants modify disease susceptibility
Neurological disease: Altered signaling in various disorders
Pharmacogenomics: Genetic variants affect CNTF therapy response

Functional Variants

Biomarker Potential

Soluble CNTFR has emerged as a potential biomarker for neurodegeneration[@iwata2024]:

Detection in cerebrospinal fluid: Correlates with disease stage
Blood-brain barrier integrity: Measures vascular health
Therapeutic monitoring: Tracks treatment response

Interactions and Signaling Network

Receptor Complex

Downstream Pathways

JAK/STAT signaling (primary)
MAPK/ERK pathway
PI3K/Akt pathway
Notch signaling crosstalk[@zhang2023]

Research Directions

Current Focus

Safe delivery methods: Overcoming blood-brain barrier through intrathecal and stereotactic delivery

Gene therapy optimization: AAV vector development with improved tropism and safety profiles

Biomarker development: Soluble CNTFR as indicator of disease progression and treatment response

Combination therapies: CNTFR with other neurotrophic factors for enhanced neuroprotection

Patient stratification: Identifying patients most likely to benefit from CNTFR-based therapies

Dosing optimization: Determining effective dosing regimens that minimize side effects

Unresolved Questions

What determines optimal CNTF dosing?
Can early intervention prevent neurodegeneration?
What is the long-term safety of gene therapy?
How do CNTFR genetic variants affect treatment response?
What is the optimal delivery route for maximum CNS exposure?

Emerging Research Areas

CNTFR splice variant biology: Understanding functional differences between variants[@park2024]
Notch pathway crosstalk: Exploiting interactions between CNTFR and Notch signaling[@zhang2023]
Astrocyte-mediated effects: Leveraging astrocyte CNTFR for neuroprotection[@singh2023]
Biomarker validation: Large-scale validation of soluble CNTFR in clinical cohorts[@iwata2024]

Future Therapeutic Directions

Engineered CNTFR agonists: Designer proteins with improved properties
Cell-penetrating peptides: Intracellular delivery of neurotrophic signals
Combination approaches: CNTFR with disease-modifying agents
Personalized medicine: Genetic profiling for treatment selection

Receptor Activation Mechanisms

Ligand Binding Dynamics

CNTFRα demonstrates sophisticated ligand binding characteristics:

CNTF Binding:

High-affinity binding (Kd ~ 10-50 pM)
Induces receptor complex trimerization
Glycosylation-dependent interaction
Soluble CNTFR can act as a decoy

Receptor Complex Formation:

CNTF binds two CNTFRα molecules

CNTFRα recruits GP130

GP130 recruits LIFRβ (in most cells)

Hexameric complex formation

JAK activation and signal initiation

Signal Amplification

The CNTFR signaling cascade demonstrates remarkable amplification:

Single CNTF molecule → receptor complex → multiple JAK molecules
JAKs activate numerous STAT3 molecules
Each p-STAT3 dimer can drive transcription of multiple target genes
Signal can amplify 10,000-fold from ligand to transcriptional response

Evolutionary Conservation

CNTFR and related receptors show evolutionary conservation:

The conservation across species underscores the fundamental importance of CNTFR-mediated signaling in nervous system function.

Structural Biology

CNTFRα Domain Architecture

The extracellular domain of CNTFRα contains several critical structural elements:

N-terminal cytokine-binding domain (CBD):

Ig-like fold with conserved disulfide bonds
Four conserved cysteine residues forming two disulfide bonds
Ligand-binding interface concentrated in this region
Contains the WSXWS motif characteristic of cytokine receptors

Fibronectin type III repeats:

Three FNIII domains
Provide structural rigidity
Serve as spacer between CBD and GPI anchor
Important for correct orientation of the CBD

GPI anchor signal:

C-terminal hydrophobic sequence
Directs protein to cell membrane via GPI modification
Enables clustering and signal amplification

Ligand-Receptor Interaction

The CNTF-CNTFR interaction has been characterized structurally:

Binding interface: Extensive contact surface between CNTF and CNTFRα
Affinities: CNTFRα binding (Kd ~ 1 nM), full complex (Kd ~ 50 pM)
Cooperativity: Binding shows positive cooperativity for dimer formation
Allosteric effects: Ligand binding triggers conformational changes

Clinical Trial Status

Historical Trials

CNTF has undergone clinical testing:

Current Developments

Recent progress includes:

AAV-CNTF delivery in animal models
CNTFR-Fc fusion proteins in development
Intrathecal delivery approaches
Biomarker-driven patient selection

External Links

[NCBI Gene: CNTFR](https://www.ncbi.nlm.nih.gov/gene/1271)
[UniProt: CNTFR](https://www.uniprot.org/uniprot/P26992)
[Ensembl: CNTFR](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000122756)
[OMIM: CNTFR](https://omim.org/entry/118400)
[Allen Brain Atlas: CNTFR](https://human.brain-map.org/microarray/search/show?search_term=CNTFR)

📖 View canonical wiki page →

CNTFR Gene

CNTFR Gene

Introduction

CNTFR Gene

Introduction

Gene Overview

Gene and Protein Structure

Chromosomal Organization

Protein Domain Architecture

Splice Variants

Protein Product and Receptor Complex

Receptor Complex Formation

Function

Signaling Mechanisms

Expression Pattern

Role in Neurodegeneration

Alzheimer's Disease

Parkinson's Disease

Motor Neuron Disease (ALS)

Neuroinflammatory Conditions

Therapeutic Targeting

Current Approaches

Agonists and Modulators

Gene Therapy Progress

Clinical Considerations

Genetic Associations

Disease-Associated Variants

Functional Variants

Biomarker Potential

Interactions and Signaling Network

Receptor Complex

Downstream Pathways

Research Directions

Current Focus

Unresolved Questions

Emerging Research Areas

Future Therapeutic Directions

Receptor Activation Mechanisms

Ligand Binding Dynamics

Signal Amplification

Evolutionary Conservation

Structural Biology

CNTFRα Domain Architecture

Ligand-Receptor Interaction

Clinical Trial Status

Historical Trials

Current Developments

See Also

External Links